摘要
病毒性呼吸道感染引起急性气道异常,包括动物和人的炎症和生理功能障碍。炎症细胞产物,如细胞因子,可能是病毒引起的气道功能障碍的主要原因。我们假设咪喹莫特,一种诱导干扰素的免疫反应增强剂,将减轻急性病毒病大鼠气道功能障碍的发展。成年棕色挪威大鼠接种副流感1型(仙台)病毒或无菌载体,用咪喹莫特或水处理。测定麻醉、瘫痪、通气大鼠的呼吸系统阻力(Rrs)、动脉血氧压(Pa,O2)、肺病毒滴度和支气管肺泡灌洗(BAL)白细胞计数。与病毒感染、咪喹莫处理的大鼠相比,病毒感染、水处理的大鼠Pa、O2显著降低,白细胞计数和Rrs显著升高,(Pa,O2, p = 0.03;白细胞计数,p = 0.02;和未感染的水处理大鼠(Pa,O2, p = 0.007;白细胞计数,p = 0.001;Rrs, p = 0.01) In addition, imiquimod suppressed BAL eosinophils in both virus-infected (p = 0.02) and noninfected (p = 0.001) groups, and lowered overall virus titres (p = 0.03). Thus, both virus-induced airway inflammation and physiological dysfunction were attenuated significantly by imiquimod treatment in this animal model. By further delineating mechanisms by which infections induce airway dysfunction in animal models, more specific pharmacological interventions can be developed for the treatment of virus-induced asthma.